S BEK1, B USTUNER1, N EREN1
1Kocaeli University Hospital, Kocaeli, Turkey
Aim: To evaluate the association between hepcidin and metabolic syndrome in chronic kidney disease (CKD).
Background: Hepcidin is an antimicrobial peptide and regulator of iron homeostasis; synthesized in the liver. Body iron and hepcidin levels are found to be related with metabolic syndrome.
Method:103 CKD patients and 59 healthy volunteers were included. Serum hepcidin levels were measured by ELISA test and compared with age, sex, body mass index, renal diseases, serum biochemistry, complete blood count, iron and total iron binding capacity, ferritin, high sensitive C- reactive protein , CRP.
Results :The mean age of the patients was 58.63 ± 11.8 years. The mean hepcidin level (30.3±24.7ng/ml) of patients was higher than the control group (17.8 ± 8.4ng/ml), (p < 0.05). Hepcidin level was significantly associated with hypertension, high uric acid levels (p<0.05). There was possitive correlation between hepcidin and urea, creatinine, ferritin, CRP, ESR, phosphorus, PTH, ALP, proteinuria and albuminuria in 24 hour urine collection (p<0.05). And negative correlation was found between hepcidin and MDRD, hemoglobin, hematocrit, calcium, 25 OH vitamin D, pH and bicarbonate levels (p<0.05). Although no correlation was found between hepcidine and glucose levels, a significant negative correlation between glucose and iron (p = 0.004, r = -0.227) was observed.
Conclusion: Hepcidin has important affects on metabolic syndrome and it’s consequences in CKD.
Biography:
I have been working in Kocaeli University Hospital as a nephrologist and will be working in Sydney University, Nephrology Department for one year from June 2018 to 2019.